2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-132821
    Irsenontrine 1429509-82-9 99.91%
    Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE9) inhibitor. Irsenontrine can be used for the research of neurological diseases.
    Irsenontrine
  • HY-133782
    Fluphenazine-N-2-chloroethane hydrochloride 3892-78-2
    Fluphenazine-N-2-chloroethane (SKF-7171A) hydrochloride is a potent irreversible calmodulin antagonist.
    Fluphenazine-N-2-chloroethane hydrochloride
  • HY-134622
    GSK-3/CDK5/CDK2-IN-1 395074-72-3 98.10%
    GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 can be used for the research of cancer, and neurodegenerative diseases.
    GSK-3/CDK5/CDK2-IN-1
  • HY-135497
    Fallypride 166173-78-0 99.93%
    Fallypride is a potent antagonist of dopamine D2/D3 receptor. Fallypride, in the form of fallypride (18F), can be used as a positron emission tomography (PET) radiotracer.
    Fallypride
  • HY-135809
    A2764 dihydrochloride 861038-72-4 99.05%
    A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K+ channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC50=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception.
    A2764 dihydrochloride
  • HY-136280
    Panamesine 139225-22-2 99.54%
    Panamesine (EMD 57445) is a sigma receptor ligand, which has a high affinity (IC50 6 nM) and selectivity for sigma binding sites. Panamesine is a potential atypical neuroleptic agent.
    Panamesine
  • HY-136424
    GPI-1485 186268-78-0 99.56%
    GPI-1485 (GM1485), a nonimmunosuppressive immunophilin ligand, promotes neurofunctional improvement and neural regeneration following stroke.
    GPI-1485
  • HY-136832
    Noribogaine hydrochloride 110514-35-7 99.9%
    Noribogaine hydrochloride is an orally active, blood-brain barrier permeable SERT inhibitor (IC50=50-300 nM) and hERG channel blocker. Noribogaine hydrochloride enhances serotonergic transmission, activates the κ-opioid receptor (OPRK) G protein signaling pathway and inhibits β-arrestin recruitment. Meanwhile, Noribogaine hydrochloride blocks the μ-opioid receptor (OPRM) signaling pathway as well as ion channels associated with cardiac repolarization. Noribogaine hydrochloride induces neuritogenesis, upregulates GDNF mRNA expression, and modulates opioid tolerance. Noribogaine hydrochloride reduces alcohol-seeking behavior in experimental animals, and is widely used in studies related to depression, addiction, alcoholism, and cardiotoxicity.
    Noribogaine hydrochloride
  • HY-136835
    GJ071 oxalate 1216676-34-4 99.74%
    GJ071 oxalate induces ATM kinase activity in ataxia telangiectasia (A-T) cells carrying homozygous TGA or TAG stop codons.
    GJ071 oxalate
  • HY-137452
    Suntinorexton 2274802-89-8 98.66%
    Suntinorexton is an OX2R agonist. Suntinorexton is used to study respiratory function during sleep.
    Suntinorexton
  • HY-138820
    SW02 1010820-68-4 98.30%
    SW02 is a potent activator of ATPase activity of Hsp70, with an EC50 of 150 μM. SW02 leads to accumulation of both total tau and phosphorylated tau (pTau).
    SW02
  • HY-139059
    ERD03 1377897-01-2 99.98%
    ERD03 is a potent disruptor of the EXOSC3-RNA interaction, with a Kd of 17±7 μM . ERD03 induces PCH1B-like phenotype in zebrafish embryo and can be used for neurological disorder disease research.
    ERD03
  • HY-139973
    OAB-14 2140911-49-3 99.21%
    OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice.
    OAB-14
  • HY-141515
    BMS-986121 313671-26-0 99.96%
    BMS-986121 is a positive allosteric modulator (PAM) of the μ opioid receptor extracted from patent WO2014107344. BMS-986121 is built on a chemical scaffold representing a new chemotype for μ receptor PAMs.
    BMS-986121
  • HY-141661
    Aβ/tau aggregation-IN-1 2252162-81-3 98.10%
    Aβ/tau aggregation-IN-1 is a potent Aβ1-42 β-sheets formation and tau aggregation inhibitor. The KD values of Aβ/tau aggregation-IN-1 with Aβ1-42 and tau are 160 μM and 337 μM, respectively. Aβ/tau aggregation-IN-1 can permeate the blood-brain barrier.
    Aβ/tau aggregation-IN-1
  • HY-142122
    Imipramine N-oxide 6829-98-7 99.90%
    Imipramine N-oxide is the metabolite of Imipramine. Imipramine N-oxide exhibits low toxicity in rat and mouse experiments. Imipramine N-oxide can be used for the research of endogenous depressions.
    Imipramine N-oxide
  • HY-14539A
    Clozapine hydrochloride 54241-01-9 99.83%
    Clozapine hydrochloride (HF 1854 hydrochloride) is an antipsychotic used for the research of schizophrenia. Clozapine hydrochloride has high affinity for a number of neuroreceptors. Clozapine hydrochloride is a potent antagonist of dopamine D2 with a Ki of 75 nM. Clozapine hydrochloride inhibits the muscarinic M1 receptor and serotonin 5HT2A receptor with Kis of 9.5 nM and 4 nM, respectively. Clozapine hydrochloride is also a potent and selective agonist at the muscarinic M4 receptor (EC50=11 nM).
    Clozapine hydrochloride
  • HY-14541R
    Olanzapine (Standard) 132539-06-1 99.98%
    Olanzapine (Standard) is the analytical standard of Olanzapine. This product is intended for research and analytical applications. Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptor (Ki=19 nM). Olanzapine is an atypical antipsychotic.
    Olanzapine (Standard)
  • HY-145430
    IL-17A modulator-1 2748749-29-1 98.80%
    IL-17A modulator-1 is a IL-17A modulator, extracted from patent WO2021239743+A1, example 9. IL-17A modulator-1 inhibits the biological action of IL-17A with a pIC50 of 8.2. IL-17A modulator-1 can be used for the research of diseases or disorders associated with modulation of IL-17A activity including diseases with an immune component or autoimmune pathol, cancer and neurodegenerative disorders.
    IL-17A modulator-1
  • HY-14608S
    L-Glutamic acid-13C 115473-51-3 99.9%
    L-Glutamic acid-13C is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-13C
Cat. No. Product Name / Synonyms Application Reactivity